Stoke Therapeutics, Inc.
STOK
$9.76
-$0.12-1.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 36.56M | 16.74M | 15.16M | 7.85M | 8.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.56M | 16.74M | 15.16M | 7.85M | 8.78M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 36.56M | 16.74M | 15.16M | 7.85M | 8.78M |
| SG&A Expenses | 48.79M | 46.56M | 44.14M | 41.33M | 41.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 137.93M | 134.05M | 129.69M | 126.30M | 123.55M |
| Operating Income | -101.37M | -117.30M | -114.53M | -118.45M | -114.77M |
| Income Before Tax | -88.98M | -105.46M | -103.57M | -108.53M | -104.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -88.98 | -105.46 | -103.57 | -108.53 | -104.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.98M | -105.46M | -103.57M | -108.53M | -104.70M |
| EBIT | -101.37M | -117.30M | -114.53M | -118.45M | -114.77M |
| EBITDA | -99.19M | -115.03M | -112.16M | -116.02M | -112.30M |
| EPS Basic | -1.68 | -2.10 | -2.19 | -2.42 | -2.38 |
| Normalized Basic EPS | -1.05 | -1.31 | -1.37 | -1.51 | -1.49 |
| EPS Diluted | -1.68 | -2.10 | -2.19 | -2.42 | -2.38 |
| Normalized Diluted EPS | -1.05 | -1.31 | -1.37 | -1.51 | -1.49 |
| Average Basic Shares Outstanding | 215.38M | 203.31M | 191.24M | 179.66M | 175.95M |
| Average Diluted Shares Outstanding | 215.38M | 203.31M | 191.24M | 179.66M | 175.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |